At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 233 enrolled
Drug / intervention
Ibrexafungerpdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Open-Label Study to Evaluate the Efficacy and Safety of SCY-078 (Ibrexafungerp) in Patients With Fungal Diseases That Are Refractory to or Intolerant of Standard Antifungal Treatment (FURI)
In Brief
A Phase 3 clinical trial evaluating Ibrexafungerp for Invasive Candidiasis and 9 related conditions. Completed, enrolled 233 participants across 37 sites in 8 countries.
Detailed Summary
This is a multicenter, open label, non-comparator, single arm study to evaluate the efficacy and safety of ibrexafungerp (SCY-078) in patients ≥ 18 years of age with a documented fungal disease that has been intolerant or refractory (rIFI) to Standard of Care (SoC) antifungal treatment.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInvasive Candidiasis, Mucocutaneous Candidiasis, Coccidioidomycosis, Histoplasmosis, Blastomycosis, Chronic Pulmonary Aspergillosis, Allergic Bronchopulmonary Aspergillosis, Invasive Pulmonary Aspergillosis, Recurrent Vulvovaginal Candidiasis, Other Emerging Fungi
CountriesAustria, Germany, Netherlands, Pakistan, South Africa, Spain, United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
2017201820192020202120222023202420252026
First PostedFeb 2017
Enrollment StartApr 2017
Primary CompletionAug 2023
TodayJul 2026
First PostedFeb 23, 2017
Enrollment StartApr 1, 2017
Primary CompletionAug 25, 2023
TodayJul 2, 2026
Enrollment to primary: 6.4 yearsPosted 9.4 years ago
Interventions
Ibrexafungerpdrug
Experimental Study Drug